Logo

Regulus to Raise $42.8M through Public Stock Offering

Jul 18, 2013
Premium

Regulus Therapeutics said this week that it has priced the public offering of 4.5 million shares of its common stock at $9.50 each.

As of midday Wednesday, Regulus’ stock was trading around $10.05 a share.

The company anticipates grossing $42.8 million from the offering, which is set to close around July 22. The underwriters of the offering have also been granted an option to purchase an additional 675,000 shares to cover overallotments.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
miRNA
Regulus
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.